Stoke Therapeutics, Inc.
General ticker "STOK" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Stoke Therapeutics, Inc. follows the US Stock Market performance with the rate: 46.7%.
Estimated limits based on current volatility of 3.1%: low 29.06$, high 30.91$
Factors to consider:
- Total employees count: 128 (+16.4%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Early stage company with limited history, Regulatory and compliance, Strategic risks and growth management, Acquisition/divestiture risks, Economic downturns and volatility
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [13.98$, 36.37$]
- 2026-12-31 to 2027-12-31 estimated range: [9.33$, 25.66$]
Financial Metrics affecting the STOK estimates:
- Negative: with PPE of -268.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: -3.75 < Return on assets ratio (scaled to [-100,100]) of -1.62
- Positive: Shareholder equity ratio, % of 84.23 > 64.29
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
Short-term STOK quotes
Long-term STOK plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $8.78MM | $36.55MM | $184.42MM |
| Operating Expenses | $123.55MM | $137.93MM | $205.01MM |
| Operating Income | $-114.77MM | $-101.37MM | $-20.59MM |
| Non-Operating Income | $10.07MM | $12.39MM | $13.71MM |
| R&D Expense | $82.23MM | $89.13MM | $137.92MM |
| Income(Loss) | $-104.70MM | $-88.98MM | $-6.88MM |
| Net Income(Loss)* | $-104.70MM | $-88.98MM | $-6.88MM |
| Stockholders Equity | $159.56MM | $229.02MM | $352.46MM |
| Assets | $228.34MM | $271.56MM | $418.43MM |
| Operating Cash Flow | $-81.07MM | $-86.85MM | $45.59MM |
| Capital expenditure | $1.62MM | $0.20MM | $0.67MM |
| Investing Cash Flow | $105.95MM | $-107.47MM | $-186.81MM |
| Financing Cash Flow | $53.01MM | $131.09MM | $97.39MM |
| Earnings Per Share** | $-2.38 | $-1.65 | $-0.12 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.